NCT06649344View on ClinicalTrials.gov

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

884

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Type 2 Diabetes

Interventions

DRUG

HRS9531 Injection

HRS9531 injected subcutaneously once weekly.

DRUG

Semaglutide Injection

Semaglutide injected subcutaneously once weekly.

Trial Locations (1)

300000

Zhu Xianyi Memorial Hospital,Tianjin Medical University, Tianjin

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06649344 - A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter